10 structural-engineering-"https:"-"https:"-"https:"-"https:" uni jobs at Center for Biologics Evaluation and Research (CBER)

FDA Computational and Experimental Assessment of Engineered Biotherapeutics: Safety and Regulatory Considerations of Synonymous Gene Recoding

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 18 days ago

how synonymous sequence changes affect mRNA structure, translation kinetics, codon usage bias, ribosome dynamics, and protein folding trajectories. You will be able to leverage in silico platforms

FDA Research Opportunity - Influenza Vaccine Assay Development

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 42 minutes ago

an understanding of protein expression systems, protein structure and purification. Mentor: The mentor for this opportunity is Jerry Weir (Jerry.Weir@fda.hhs.gov ). If you have questions about the nature

FDA Focus Towards More Efficient Factor VIII Drug Products to Improve the Treatment of Hemophilia A

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 15 days ago

vitro. Gene/construct design, recombinant protein expression, purification, and testing. Various structural and functional assays modeling the biomolecule interactions in vitro. The most recent

FDA Research Opportunity - Bacteriophage Therapy

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 1 day ago

will proceed on multiple fronts including mouse models of infection and phage treatment, isolation of mutant bacterial and bacteriophage strains, genetic engineering of bacterial and bacteriophage

FDA Evaluation and Characterization of Neutralizing Antibodies Against Viruses Relevant to Blood-Derived Products

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 18 days ago

et al., Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein. J Virol 86, 12686-12694 (2012). 3. L. Deng et al., Structural

FDA Research Opportunity - Detection of Emerging Pathogens that Threaten Blood Safety

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | 17 days ago

them access to unique research opportunities, top scientists and engineers, and state-of the art facilities and equipment. Research Project: This research project focuses on detection of emerging and re

FDA Research Opportunity - Developing Methods for Efficient Gene Editing in Hematopoietic Stem Cells (HSCs)

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 39 minutes ago

expansion protocols. You will gain comprehensive training in the design, development, and optimization of novel lipid nanoparticle (LNP) formulations specifically engineered for efficient gene editing in HSCs

FDA Evaluation of Platelets: Antimicrobial Treatments and Evaluation of the Treated Products for Functions

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | 18 days ago

them access to unique research opportunities, top scientists and engineers, and state-of the art facilities and equipment. Research Project: Under the guidance of Dr. Atreya, you will be involved in

FDA Tick-Borne Pathogen Research Program

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | 5 days ago

an assigned mentor, participants have authentic hands-on research experience and allows them access to unique research opportunities, top scientists and engineers, and state-of the art facilities and equipment

FDA Research Opportunity in Developing Methods for Efficient Gene Editing in Hematopoietic Stem Cells (HSCs)

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 18 days ago

expansion protocols. You will gain comprehensive training in the design, development, and optimization of novel lipid nanoparticle (LNP) formulations specifically engineered for efficient gene editing in HSCs